Satellos Bioscience Inc. MSCLF
6.25 USD 0.00 (+0.00%)
Apr 8, 2026, 9:30 AM EDT
5.77 Day range 6.39
0.88 52-week range 12.50
- YTD
- +6.29%
- 1 year
- -5.16%
- Market cap
- 96.62M
- EPS (ttm)
- 2.57
- P/E ratio
- 2.43
- YTD return
- +6.29%
- 1-year return
- -5.16%
- Volume
- 62.40K
- Avg volume
- 12.13K
- Open
- 5.79
- Previous close
- 6.25
- Day's range
- 5.77 – 6.39
- 52-week range
- 0.88 – 12.50
No chart data for this range yet.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.05 | -0.06 | -0.01 | -20.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.05 | -0.04 | +0.01 | +20.00% |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.04 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | -0.01 | -0.04 | -0.03 | -300.00% |
| Nov 22, 2023 | Sep 1, 2023 | -0.02 | -0.02 | 0.00 | 0.00% |
| Aug 28, 2023 | Jun 1, 2023 | -0.03 | -0.04 | -0.01 | -33.33% |
News
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience 
Satellos to Participate in Upcoming Investor Conferences 
Satellos Granted Composition of Matter Patent for Forazapadin 
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy 
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development 
Satellos to Present at the 31st Annual Congress of the World Muscle Society 
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 
Satellos to Participate in Upcoming Investor Conferences 
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress 
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Your note
Sign in to keep a note on MSCLF — it syncs with the Stock Master app.